The role of genetically engineered pigs in xenotransplantation research

Journal of Pathology

Volumn 238, Issue 2, 2016, Pages 288-299

  Cooper, David K C ^a   Ekser, Burcin ^b   Ramsoondar, Jagdeece ^c   Phelps, Carol ^c   Ayares, David ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c REVIVICOR INC   (United States)

Author keywords

genetically engineered; islets; non human primate; organs; pig; xenotransplantation

Indexed keywords

C REACTIVE PROTEIN; ANTIGEN; COMPLEMENT; DISACCHARIDE; GALACTOSYL-(1-3)GALACTOSE;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; CELL ACTIVATION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; GENETIC ENGINEERING; GENETIC MANIPULATION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MICROANGIOPATHY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION; ANIMAL; BLOOD COAGULATION DISORDERS; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); GENETICS; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; INFLAMMATION; MEDICAL RESEARCH; METABOLISM; PATIENT SAFETY; PHYSIOLOGY; PIG; PRIMATE; PROCEDURES; T LYMPHOCYTE; TRANSGENIC ANIMAL; TRANSPLANTATION; XENOGRAFT;

ADAPTIVE IMMUNITY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS; BIOMEDICAL RESEARCH; BLOOD COAGULATION DISORDERS; CLINICAL TRIALS AS TOPIC; COMPLEMENT SYSTEM PROTEINS; DISACCHARIDES; GENETIC ENGINEERING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; PATIENT SAFETY; PRIMATES; SWINE; T-LYMPHOCYTES; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84951278691     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4635     Document Type: Review

References (136)

1. Cooper DK,. The case for xenotransplantation. Clin Transpl 2015; 29: 288-293.
2. Taniguchi S, Cooper DK,. Clinical xenotransplantation: past, present and future. Ann R Coll Surg Engl 1997; 79: 13-19.
3. Cooper DK,. A brief history of cross-species organ transplantation. Proc Bayl Univ Med Cent 2012; 25: 49-57.
4. Alexandre GPJ, Gianello P, Latinne D, et al., Plasmapheresis and splenectomy in experimental renal xenotransplantation. In Xenograft 25, Hardy M., Excerpta Medica: Amsterdam, New York, Oxford, 1989; 259-266.
5. Alexandre GP, De Bruyere M, Squifflet JP, et al., Human ABO-incompatible living donor renal homografts. Neth J Med 1985; 28: 231-234.
6. Alexandre GP, Squifflet JP, De Bruyere M, et al., Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transpl Proc 1987; 19: 4538-4542.
7. Cooper DK, Ye Y, Niekrasz M, et al., Specific intravenous carbohydrate therapy. A new concept in inhibiting antibody-mediated rejection-experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993; 56: 769-777.
8. Alexandre GP,. From ABO-incompatible human kidney transplantation to xenotransplantation. Xenotransplantation 2004; 11: 233-236.
9. Stussi G, West L, Cooper DK, et al., ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation 2006; 13: 390-399.
10. Kobayashi T, Cooper DK,. Anti-Gal, α-Gal epitopes, and xenotransplantation. Subcell Biochem 1999; 32: 229-257.
11. Lambrigts D, Sachs DH, Cooper DK,. Discordant organ xenotransplantation in primates: world experience and current status. Transplantation 1998; 66: 547-561.
12. Cooper DK, Satyananda V, Ekser B, et al., Progress in pig-to-nonhuman primate transplantation models (1998-2013): a comprehensive review of the literature. Xenotransplantation 2014; 21: 397-419.
13. Atkinson JP, Oglesby TJ, White D, et al., Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86 (suppl 1): 27-30.
14. Dalmasso AP, Vercellotti GM, Platt JL, et al., Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530-533.
15. White DJ, Oglesby T, Liszewski MK, et al., Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl Int 1992; 5 (suppl 1): S648-650.
16. White DJG, Langford GA, Cozzi E, et al., Production of pigs trangenic for human DAF: a strategy for xenotransplantation. Xenotransplantation 1995; 2: 213-217.
17. Rosengard AM, Cary NR, Langford GA, et al., Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325-1333.
18. Cozzi E, White DJ,. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
19. Cozzi E, Yannoutsos N, Langford GA, et al., Effects of transgenic expression of human decay accelerating factor on the inhibition of hyperacute rejection of pig organs. In Xenotransplantation-The Transplantation of Organs and Tissues betwen Species, 2nd edn, Cooper D, Kemp E, Platt JL, White DJG, (eds). Springer: Berlin, 1997; 665-682.
20. Campbell KH, McWhir J, Ritchie WA, et al., Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996; 380: 64-66.
21. Polejaeva IA, Chen SH, Vaught TD, et al., Cloned pigs produced by nuclear transfer from adult somatic cells. Nature 2000; 407: 86-90.
22. Cooper DK, Koren E, Oriol R,. Genetically engineered pigs. Lancet 1993; 342: 682-683.
23. Phelps CJ, Koike C, Vaught TD, et al., Production of α1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
24. Kolber-Simonds D, Lai L, Watt SR, et al., Production of α1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 2004; 101: 7335-7340.
25. Kuwaki K, Tseng YL, Dor FJ, et al., Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
26. Tseng YL, Kuwaki K, Dor FJ, et al., α1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80: 1493-1500.
27. Yamada K, Yazawa K, Shimizu A, et al., Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32-34.
28. Hisashi Y, Yamada K, Kuwaki K, et al., Rejection of cardiac xenografts transplanted from α1,3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons. Am J Transpl 2008; 8: 2516-2526.
29. Shimizu A, Yamada K, Yamamoto S, et al., Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005; 16: 2732-2745.
30. Shimizu A, Hisashi Y, Kuwaki K, et al., Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from α1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172: 1471-1481.
31. McGregor CG, Ricci D, Miyagi N, et al., Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation 2012; 93: 686-692.
32. Azimzadeh A, Kelishadi S, Ezzelarab M, et al., Early graft failure of GTKO pig organs in baboons is reduced in hCPRP expression. Xenotransplantation 2009; 16: 356 [abstract].
33. Azimzadeh A, Kelishadi S, Ezzelarab MB, et al. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement-regulatory protein. Xenotransplantation 2015: in press.
34. Houser SL, Kuwaki K, Knosalla C, et al., Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
35. Buhler L, Basker M, Alwayn IP, et al., Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 1323-1331.
36. Cowan PJ, Aminian A, Barlow H, et al., Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
37. Lin CC, Ezzelarab M, Shapiro R, et al., Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transpl 2010; 10: 1556-1568.
38. Robson SC, Cooper DK, d'Apice AJ,. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7: 166-176.
39. Cowan PJ, Roussel JC, d'Apice AJ,. The vascular and coagulation issues in xenotransplantation. Curr Opin Organ Transpl 2009; 14: 161-167.
40. Cowan PJ, Robson SC, d'Apice AJ,. Controlling coagulation dysregulation in xenotransplantation. Curr Opin Organ Transpl 2011; 16: 214-221.
41. Ayares D, Vaught T, Ball S, et al., Genetic engineering of source pigs for xenotransplantation: progress and prospects. Xenotransplantation 2013; 20: 361 [abstract 408].
42. Roussel JC, Moran CJ, Salvaris EJ, et al., Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transpl 2008; 8: 1101-1112.
43. Petersen B, Ramackers W, Tiede A, et al., Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16: 486-495.
44. Miwa Y, Yamamoto K, Onishi A, et al., Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 2010; 17: 26-37.
45. Lee KF, Salvaris EJ, Roussel JC, et al., Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008; 15: 191-197.
46. Ahrens HE, Petersen B, Herrmann D, et al., siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation. Am J Transpl 2015; 15: 1407-1414.
47. Mohiuddin MM, Singh AK, Corcoran PC, et al., Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. J Thorac Cardiovasc Surg 2014; 148: 1106-1113; discussion, 1113-1104.
48. Mohiuddin MM, Singh AK, Corcoran PC, et al., Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. Xenotransplantation 2014; 21: 35-45.
49. Mohiuddin MM, Singh AK, Corcoran PC, et al., One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transpl 2014; 14: 488-489.
50. Higginbotham L, Mathews D, Breeden CA, et al., Pre-transplant antibody screening and anti-CD154 co-stimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. Xenotransplantation 2015; 22: 221-230.
51. Iwase H, Liu H, Wijkstrom M, et al., Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. Xenotransplantation 2015: in press.
52. Schirmer JM, Fass DN, Byrne GW, et al., Effective antiplatelet therapy does not prolong transgenic pig-to-baboon cardiac xenograft survival. Xenotransplantation 2004; 11: 436-443.
53. Byrne GW, Schirmer JM, Fass DN, et al., Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transpl 2005; 5: 1011-1020.
54. Byrne GW, Davies WR, Oi K, et al., Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82: 1787-1791.
55. Bouhours D, Pourcel C, Bouhours JE,. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal α1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconj J 1996; 13: 947-953.
56. Padler-Karavani V, Varki A,. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011; 18: 1-5.
57. Lutz AJ, Li P, Estrada JL, et al., Double knockout pigs deficient in N-glycolylneuraminic acid and galactose α1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013; 20: 27-35.
58. Li P, Estrada JL, Burlak C, et al., Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection. Xenotransplantation 2015; 22: 20-31.
59. Estrada JL, Martens G, Li P, et al., Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes. Xenotransplantation 2015; 22: 194-202.
60. Byrne GW, Du Z, Stalboerger P, et al., Cloning and expression of porcine β1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen. Xenotransplantation 2014; 21: 543-554.
61. Ezzelarab MB, Ekser B, Azimzadeh A, et al., Systemic inflammation in xenograft recipients precedes activation of coagulation. Xenotransplantation 2015; 22: 32-47.
62. Iwase H, Ekser B, Zhou H, et al., Further evidence for a sustained systemic inflammatory response in xenograft recipients (SIXR). Xenotransplantation 2015; 22: 399-405.
63. Oropeza M, Petersen B, Carnwath JW, et al., Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 2009; 16: 522-534.
64. Petersen B, Lucas-Hahn A, Lemme E, et al., Generation and characterization of pigs transgenic for human hemeoxygenase-1 (hHO-1). Xenotransplantation 2010; 17: 102-103.
65. Petersen B, Ramackers W, Lucas-Hahn A, et al., Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation 2011; 18: 355-368.
66. Chen G, Qian H, Starzl T, et al., Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11: 1295-1298.
67. McGregor CG, Davies WR, Oi K, et al., Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
68. Teotia SS, Walker RC, Schirmer JM, et al., Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival. Xenotransplantation 2005; 12: 127-133.
69. Buhler L, Awwad M, Basker M, et al., High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000; 69: 2296-2304.
70. Iwase H, Ekser B, Satyananda V, et al., Pig-to-baboon heart transplantation-first experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 2015; 22: 211-220.
71. Ezzelarab MB, Ekser B, Echeverri G, et al., Costimulation blockade in pig artery patch xenotransplantation-a simple model to monitor the adaptive immune response in nonhuman primates. Xenotransplantation 2012; 19: 221-232.
72. Iwase H, Satyananda V, Zhou H, et al., Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs. Transpl Immunol 2015; 32: 99-108.
73. Ezzelarab C, Ayares D, Cooper DK, et al., Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells. Xenotransplantation 2012; 19: 311-316.
74. Satyananda V, Hara H, Ezzelarab MB, et al., New concepts of immune modulation in xenotransplantation. Transplantation 2013; 96: 937-945.
75. Wilhite T, Ezzelarab C, Hara H, et al., The effect of Gal expression on pig cells on the human T-cell xenoresponse. Xenotransplantation 2012; 19: 56-63.
76. Ezzelarab M, Ezzelarab C, Wilhite T, et al., Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation 2011; 18: 183-195.
77. Ezzelarab MB, Ayares D, Cooper DKC,. Transgenic expression of human CD46 reduces primate T cell responses to pig cells in vitro. Xenotransplantation 2015; in press.
78. Phelps CJ, Ball SF, Vaught TD, et al., Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009; 16: 477-485.
79. Bottino R, Wijkstrom M, van der Windt DJ, et al., Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transpl 2014; 14: 2275-2287.
80. Wijkstrom M, Bottino R, Iwase H, et al., Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation 2015; 22: 70-79.
81. Martin C, Plat M, Nerriere-Daguin V, et al., Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005; 14: 373-384.
82. Leveque X, Cozzi E, Naveilhan P, et al., Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression. Curr Opin Organ Transpl 2011; 16: 190-194.
83. Phelps C, Dai Y, Ball S, et al., Production of transgenic pigs with down-regulation of SLA Class II on a GTKO/CD46 genetic background. In 12th Congress of the International Xenotransplantation Association, Osaka, Japan, 2013; abstract 262.
84. Hara H, Witt W, Crossley T, et al., Human dominant-negative class II transactivator transgenic pigs-effect on the human anti-pig T-cell immune response and immune status. Immunology 2013; 140: 39-46.
85. Reyes LM, Estrada JL, Wang ZY, et al., Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. J Immunol 2014; 193: 5751-5757.
86. Tena A, Kurtz J, Leonard DA, et al., Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation. Am J Transpl 2014; 14: 2713-2722.
87. Inverardi L, Clissi B, Stolzer AL, et al., Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997; 63: 1318-1330.
88. Baumann BC, Forte P, Hawley RJ, et al., Lack of galactose-α1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004; 172: 6460-6467.
89. Rieben R, Seebach JD,. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005; 26: 2-5.
90. Horvath-Arcidiacono JA, Porter CM, Bloom ET,. Human NK cells can lyse porcine endothelial cells independent of their expression of Gal α(1,3)-Gal and killing is enhanced by activation of either effector or target cells. Xenotransplantation 2006; 13: 318-327.
91. Kennett SB, Porter CM, Horvath-Arcidiacono JA, et al., Characterization of baboon NK cells and their xenogeneic activity. Xenotransplantation 2010; 17: 288-299.
92. Seebach JD, Comrack C, Germana S, et al., HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655-3661.
93. Dorling A, Monk NJ, Lechler RI,. HLA-G inhibits the transendothelial migration of human NK cells. Eur J Immunol 2000; 30: 586-593.
94. Forte P, Pazmany L, Matter-Reissmann UB, et al., HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 2001; 167: 6002-6008.
95. Crew MD,. Play it in E or G: utilization of HLA-E and -G in xenotransplantation. Xenotransplantation 2007; 14: 198-207.
96. Weiss EH, Lilienfeld BG, Muller S, et al., HLA-E/human β2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 2009; 87: 35-43.
97. Maeda A, Kawamura T, Ueno T, et al., The suppression of inflammatory macrophage-mediated cytotoxicity and proinflammatory cytokine production by transgenic expression of HLA-E. Transpl Immunol 2013; 29: 76-81.
98. Esquivel EL, Maeda A, Eguchi H, et al., Suppression of human macrophage-mediated cytotoxicity by transgenic swine endothelial cell expression of HLA-G. Transpl Immunol 2015; 32: 109-115.
99. Forte P, Baumann BC, Weiss EH, et al., HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transpl 2005; 5: 2085-2093.
100. Soin B, Smith KG, Zaidi A, et al., Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int 2001; 60: 1592-1597.
101. Ibrahim Z, Busch J, Awwad M, et al., Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. Xenotransplantation 2006; 13: 488-499.
102. van der Windt DJ, Bottino R, Casu A, et al., Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transpl 2009; 9: 2716-2726.
103. Ekser B, Long C, Echeverri GJ, et al., Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transpl 2010; 10: 273-285.
104. Burlak C, Paris LL, Chihara RK, et al., The fate of human platelets perfused through the pig liver: implications for xenotransplantation. Xenotransplantation 2010; 17: 350-361.
105. Ezzelarab M, Ekser B, Gridelli B, et al., Thrombocytopenia after pig-to-baboon liver xenotransplantation: where do platelets go? Xenotransplantation 2011; 18: 320-327.
106. Burlak C, Paris LL, Lutz AJ, et al., Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs. Am J Transpl 2014; 14: 1895-1900.
107. Paris LL, Estrada JL, Li P, et al., Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein. Xenotransplantation 2015; 22: 203-210.
108. Ekser B, Echeverri GJ, Hassett AC, et al., Hepatic function after genetically engineered pig liver transplantation in baboons. Transplantation 2010; 90: 483-493.
109. Onions D, Cooper DK, Alexander TJ, et al., An approach to the control of disease transmission in pig-to-human xenotransplantation. Xenotransplantation 2000; 7: 143-155.
110. Fishman JA, Patience C,. Xenotransplantation: infectious risk revisited. Am J Transpl 2004; 4: 1383-1390.
111. Denner J, Tonjes RR,. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev 2012; 25: 318-343.
112. Smith DM,. Endogenous retroviruses in xenografts. N Engl J Med 1993; 328: 142-143.
113. Dieckhoff B, Karlas A, Hofmann A, et al., Inhibition of porcine endogenous retroviruses (PERVs) in primary porcine cells by RNA interference using lentiviral vectors. Arch Virol 2007; 152: 629-634.
114. Dieckhoff B, Petersen B, Kues WA, et al., Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. Xenotransplantation 2008; 15: 36-45.
115. Ramsoondar J, Vaught T, Ball S, et al., Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation 2009; 16: 164-180.
116. Hsu PD, Lander ES, Zhang F,. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278.
117. Kim H, Kim JS,. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014; 15: 321-334.
118. Bibikova M, Golic M, Golic KG, et al., Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002; 161: 1169-1175.
119. Urnov FD, Rebar EJ, Holmes MC, et al., Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11: 636-646.
120. Hauschild J, Petersen B, Santiago Y, et al., Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc Natl Acad Sci USA 2011; 108: 12013-12017.
121. Tesson L, Usal C, Menoret S, et al., Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29: 695-696.
122. Galli C, Perota A, Brunetti D, et al., Genetic engineering including superseding microinjection: new ways to make GM pigs. Xenotransplantation 2010; 17: 397-410.
123. Seruggia D, Montoliu L,. The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals. Transgenic Res 2014; 23: 707-716.
124. Doudna JA, Charpentier E,. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 1258096.
125. Ni W, Qiao J, Hu S, et al., Efficient gene knockout in goats using CRISPR-Cas9 system. PLoS One 2014; 9: e106718.
126. Mali P, Esvelt KM, Church GM,. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10: 957-963.
127. Cooper DK, Ekser B, Burlak C, et al., Clinical lung xenotransplantation-what donor genetic modifications may be necessary? Xenotransplantation 2012; 19: 144-158.
128. Wynyard S, Nathu D, Garkavenko O, et al., Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.
129. Zhang MC, Liu X, Jin Y, et al., Lamellar keratoplasty treatment of fungal corneal ulcers with acellular porcine corneal stroma. Am J Transpl 2015; 15: 1068-1075.
130. Hara H, Ezzelarab M, Rood PP, et al., Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation 2006; 13: 357-365.
131. Wong BS, Yamada K, Okumi M, et al., Allosensitization does not increase the risk of xenoreactivity to α1,3-galactosyltransferase gene-knockout miniature swine in patients on transplantation waiting lists. Transplantation 2006; 82: 314-319.
132. Cooper DK, Tseng YL, Saidman SL,. Alloantibody and xenoantibody cross-reactivity in transplantation. Transplantation 2004; 77: 1-5.
133. Ye Y, Luo Y, Kobayashi T, et al., Secondary organ allografting after a primary 'bridging' xenotransplant. Transplantation 1995; 60: 19-22.
134. Baertschiger RM, Dor FJ, Prabharasuth D, et al., Absence of humoral and cellular alloreactivity in baboons sensitized to pig antigens. Xenotransplantation 2004; 11: 27-32.
135. Cooper DKC, Bottino R,. Recent advances in understanding xenotransplantation: implications for the clinic. Expert Rev Clin Immunol 2015; in press.
136. Byrne GW, Azimzadeh AM, Ezzelarab M, et al,. Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection. Xenotransplantation 2013; 20: 292-307.